Investigational therapies targeted to the treatment of benign prostatic hyperplasia

Author： Gravas Stavros   de la Rosette Jean JMCH  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.22, Iss.3, 2013-03, pp. : 357-368

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benign prostatic hyperplasia: an insight into current investigational medical therapies

By Tiwari Atul   Krishna N S   Nanda Kamna   Chugh Anita  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 11, 2005-11 ,pp. : 1359-1372

Informa Healthcare

Access to resources Recommend Favorite

NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia

By Shore Neal  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 305-310

Informa Healthcare

Access to resources Recommend Favorite

Treatment options for benign prostatic hyperplasia

By Thurlow R.J.  

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 225-246

Informa Healthcare

Access to resources Recommend Favorite

Dutasteride for the treatment of benign prostatic hyperplasia

By Wu Christopher   Kapoor Anil  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1399-1408

Informa Healthcare

Access to resources Recommend Favorite

Combination Pharmacological Therapies for the Management of Benign Prostatic Hyperplasia

By Cohen Seth A.   Parsons J. Kellogg  

Drugs & Aging, Vol. 29, Iss. 4, 2012-04 ,pp. : 275-284

Adis International

Access to resources Recommend Favorite